SAN ANTONIO University Hospital and UT Health San Antonio are again on the cutting edge in the battle against COVID-19, announcing the start of the third phase of clinical trials involving the drug remdesivir.
This time, remdesivir will be paired with a drug called interferon beta-1a, which the U.S. Food and Drug Administration has already approved for multiple sclerosis patients.
Now, we realize this is an ultra marathon, said Dr. Thomas Patterson, the lead COVID-19 clinician for University Hospital.
UT Health San Antonio and University Hospital are among the first test sites in the nation for this trial.
Five patients have already enrolled in San Antonio, joining potentially a total of 1,000 volunteers nationwide.